Medications Shape Your Gut Ecosystem
Beyond antibiotics, many commonly prescribed medications significantly impact the gut microbiome, intestinal permeability, and digestive function. A 2020 Nature Communications study screened over 1,000 marketed drugs and found that 24 percent of non-antibiotic medications had antimicrobial activity — meaning they suppressed gut bacterial growth at therapeutic concentrations. Understanding these effects enables more informed prescribing and patient-clinician conversations.
Proton Pump Inhibitors (PPIs)
PPIs (omeprazole, lansoprazole, pantoprazole) are among the most widely prescribed medications globally. By suppressing gastric acid production, they remove a key barrier to bacterial entry into the upper GI tract, increasing the risk of SIBO, C. difficile infection, and community-acquired pneumonia. PPI use is associated with reduced microbial diversity and increased Streptococcus, Enterococcus, and Staphylococcus abundance. Long-term use (beyond 8 weeks without reassessment) is frequently unnecessary, and deprescribing should be discussed with patients on long-term PPIs without a clear ongoing indication.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs (ibuprofen, naproxen, diclofenac) damage the intestinal mucosa through COX-1 inhibition (reducing protective prostaglandin production) and direct topical toxicity to epithelial cells. NSAID enteropathy — mucosal inflammation in the small intestine — is detectable on capsule endoscopy in up to 70 percent of chronic NSAID users, even when they have no symptoms. NSAIDs also increase intestinal permeability and elevate fecal calprotectin, potentially mimicking IBD on screening tests.
Metformin
As discussed previously, metformin reshapes the gut microbiome — increasing Akkermansia muciniphila and altering bile acid metabolism — and a significant portion of its glucose-lowering effect is microbiome-mediated. The GI side effects (bloating, diarrhoea, nausea) that affect up to 30 percent of patients are largely driven by these microbial shifts.
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs affect serotonin signalling in the gut as well as the brain. They can cause diarrhoea (by increasing colonic serotonin-driven motility) or, less commonly, constipation. Additionally, SSRIs have been shown to have direct antimicrobial effects against certain gut bacteria at therapeutic concentrations — a finding that adds complexity to their clinical profile.
Opioids
Opioids slow colonic transit through mu-receptor-mediated inhibition of motility, producing opioid-induced constipation (OIC) in 40 to 80 percent of chronic users. Prolonged transit time alters microbial composition (favouring methane-producing archaea), reduces SCFA production, and increases intestinal permeability. OIC is a significant quality-of-life issue and should be proactively managed with peripheral mu-opioid receptor antagonists (naloxegol, methylnaltrexone) rather than simply adding laxatives.
The Conversation
Medication review should be a standard component of gut health assessment. Ask your doctor: Is each medication still indicated? Is the dose optimised? Are there alternatives with fewer GI effects? Can any medications be safely deprescribed? This is not about stopping necessary treatment — it is about optimising the pharmacological environment in which your gut operates.